

El-Hibri Fuad
Form 4
April 21, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
El-Hibri Fuad

(Last) (First) (Middle)

2273 RESEARCH BLVD, SUITE 400

(Street)

ROCKVILLE, MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Emergent BioSolutions Inc. [EBS]

3. Date of Earliest Transaction (Month/Day/Year)

04/17/2008

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

CEO & Chariman

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price (1) (2) (3)
Common Stock	04/17/2008		J(1)(2)(3)		332,984	D	7,981,835 (1) (2) (3)
Common Stock							246,992 (4)
Common Stock							3,665,043 (4) I
Common Stock							1,559,155 (5) I
							719,275 (6) I
							By Intervac, L.L.C.
							By BioPharm, L.L.C.
							By Biovac, L.L.C.

Common
Stock

By Intervac
Managment,
L.L.C.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Transaction (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
El-Hibri Fuad 2273 RESEARCH BLVD, SUITE 400 ROCKVILLE, MD 20850	X	X	CEO & Chariman	

Signatures

/s/Denise Esposito,
attorney-in-fact
**Signature of Reporting Person

04/21/2008
Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) On August 16, 2007, the father of Fuad El-Hibri gave him a gift of the capital stock of an entity that held equity interests in Intervac, L.L.C. such that Mr. El-Hibri acquired indirect beneficial ownership of a 4.0046% equity interest in Intervac, L.L.C., which increased the equity interest in Intervac, L.L.C. held by Mr. El-Hibri, together with the equity interest directly held by himself and his wife, as tenants by the entirety, to 36.5046% in aggregate.

Edgar Filing: El-Hibri Fuad - Form 4

- (2) On April 17, 2008, Intervac, L.L.C. redeemed a 4.0047% equity interest of a member of Intervac, L.L.C. in exchange for a transfer of 332,984 shares of Common Stock of the issuer to such member. As a result, Intervac, L.L.C. is now the direct owner of 7,981,835 shares of Common Stock of the issuer.

- (3) As a result of the redemption, the ownership interests in Intervac, L.L.C. of all members increased proportionately. Accordingly, the equity interest in Intervac, L.L.C. indirectly held by Mr. El-Hibri, together with the equity interest directly held with his wife, as tenants by the entirety, in Intervac, L.L.C., increased to 38.0276% in the aggregate. This increased ownership percentage in a smaller number of shares of Common Stock of the issuer had no effect on Mr. El-Hibri's pecuniary interest in shares of Common Stock of the issuer. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 3,035,300 shares.

- (4) On April 16, 2008, BioPharm, L.L.C. made a pro rata distribution of 400,000 shares of Common Stock for no consideration that reduced Mr. El-Hibri's indirect ownership through BioPharm, L.L.C. by 400,000 shares. As a result of the pro rata distribution, Mr. El-Hibri received 160,680 shares of Common Stock from BioPharm, L.L.C. for no consideration that he now holds directly. Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 3,665,043 shares of Common Stock following the above-referenced in-kind pro rata distribution to its members for no consideration. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,472,248 shares.

- (5) Mr. El-Hibri holds with his wife, as tenants by the entirety, a 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,599,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 1,426,446 shares.

- (6) Mr. El-Hibri holds with his wife, as tenants by the entirety, a 31.11% equity interest in Intervac Management, L.L.C. Intervac Management, L.L.C. is the direct owner of 719,275 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 223,766 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.